FASCINATE THERAPEUTICS
FAScinate is a clinical-stage company that develops disease-modifying drugs for neurodegenerative diseases such as Parkinson's disease (PD) and multiple system atrophy (MSA).
FASCINATE THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2018-01-01
Status:
Active
Contact:
(858) 630-8540
Email Addresses:
[email protected]
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Fast Access Specialty Therapeutics
Fast Access Specialty Therapeutics is a specialty pharmacy company.
Syndya Therapeutics
Syndya Therapeutics is a 3D combinatorial, phenotypic screening company.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-15 | Egret Therapeutics | FAScinate Therapeutics investment in Seed Round - Egret Therapeutics | N/A |
More informations about "FAScinate Therapeutics"
About Us - fascinatetherapeutics.com
FAScinate is a clinical stage company that develops disease-modifying drugs for neurodegenerative diseases such as Parkinson’s disease (PD) and multiple system atrophy (MSA). FAScinate Therapeutics was founded in 2018 as a …See details»
FAScinate Therapeutics - Crunchbase Investor Profile & Investments
Legal Name FAScinate Therapeutics, Inc. Investor Type Private Equity Firm, Venture Capital Contact Email [email protected]; Phone Number (858) 630-8540; …See details»
Fascinate Therapeutics , Inc. - Drug pipelines, Patents, Clinical ...
Clinical Trials associated with Fascinate Therapeutics , Inc. NCT05670782 / Active, not recruiting Phase 2. A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and …See details»
FAScinate Therapeutics - PitchBook
FAScinate Therapeutics General Information Description. Developer of novel drugs and therapeutics intended to treat Parkinson's disease. The company develops drugs for …See details»
Organization | FAScinate Therapeutics Inc. - Purdue University
Organization Overview. First Clinical Trial. 2022 NCT05670782. First Marketed Drug. None First NDA Approval. None Last Known Activity ... FAScinate Therapeutics Inc. Active Ingredients. …See details»
Fascinate Therapeutics, Inc. Company Profile | San Diego, CA ...
Find company research, competitor information, contact details & financial data for Fascinate Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
FAScinate Therapeutics Inc. Submits Investigational New Drug …
SAN DIEGO (PRWEB) NOVEMBER 02, 2021 FAScinate Therapeutics today announced that it has submitted an Investigational New Drug (IND) Application for Phase 2 clinical trials of its …See details»
FAScinate Therapeutics - Company Profile - Tracxn
Oct 22, 2024 FAScinate Therapeutics ranks 266th among 423 active competitors. 152 of its competitors are funded while 73 have exited. Overall, FAScinate Therapeutics and its …See details»
FAScinate Therapeutics - VentureRadar
FAScinate Therapeutics Follow Following Location: USA. Founded in 2018. Privately Held " FAScinate is a clinical stage company that develops disease-modifying drugs for …See details»
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical ... - PRWeb
Nov 17, 2021 FAScinate Therapeutics Inc., a subsidiary of the Korean Biotech company Kainos Medicine Inc., is a clinical stage biotechnology company based in San Diego, California …See details»
KM-819 for the Treatment of Parkinson’s Disease Demonstrates …
FAScinate Therapeutics announces positive Phase 2 trial results for KM-819, a promising treatment for Parkinson’s, showing potential neuroprotective effects. ... Sara supports strategic …See details»
FAScinate Therapeutics - VentureRadar
FAScinate is a clinical stage company that develops disease-modifying drugs for neurodegenerative diseases such as Parkinson’s disease (PD) and multiple system atrophy …See details»
Potential Parkinson's Therapy, KM-819, Set for Phase 2 Trial
Nov 19, 2021 Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the …See details»
Parkinson Disease Agent KM-819 Demonstrates Safe
Jan 24, 2023 According to a recent announcement, Part 1A, the initial stage of a phase 2 study (NCT05670782) assessing FAScinate Therapeutics’ Parkinson disease (PD) candidate KM …See details»
KM-819 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 FDA Approves FAScinate’s Application for Phase 2 Trials with “KM-819” Treatment SAN DIEGO (PRWEB) NOVEMBER 17, 2021 Clinical stage drug development …See details»
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of ...
Nov 17, 2021 FDA Approves FAScinate’s Application for Phase 2 Trials with “KM-819” Treatment . SAN DIEGO (PRWEB) NOVEMBER 17, 2021 Clinical stage drug development …See details»
News/Publications - fascinatetherapeutics.com
Nov 17, 2021 FAScinate Therapeutics Completes Part 1a of Phase 2 Study of Company's Parkinson’s Disease Drug Candidate "KM-819" Read Now > Thursday, January 12, 2023 / …See details»
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of ...
Nov 17, 2021 FDA Approves FAScinate’s Application for Phase 2 Trials with “KM-819” Treatment. SAN DIEGO (PRWEB) NOVEMBER 17, 2021. Clinical stage drug development …See details»
Product Overview - fascinatetherapeutics.com
Parkinson’s disease (PD) is the second most common neurodegenerative condition. It progresses gradually, but inevitably—causing the death of dopaminergic neuron cells, which impacts the …See details»